In vivo and in vitro genotoxicity studies of Semelil (ANGIPARS™)

Daru

Volumn 16, Issue SUPPL. 1, 2008, Pages 20-24

  Khorram Khorshid, H R ^a   Sadeghi, B ^b   Heshmat, R ^c   Abdollahi, M ^d   Salari, P ^d   Farzamfar, B ^e   Madani, S H ^f  

^a UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^b KAROLINSKA INSTITUTE   (Sweden)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e PASTEUR INSTITUTE OF IRAN   (Iran)

^f Rabe Rashidi Institute Iran   (Iran)

Author keywords

ANGIPARS ; Genotoxicity; Melilotus officinalis; Mutagenicity; Semelil

Indexed keywords

ANGIPARS; HERBACEOUS AGENT; SEMELIL; UNCLASSIFIED DRUG;

AMES TEST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CHROMOSOME ABERRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; GENOTOXICITY; GERM CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUTAGENICITY; MUTATIONAL ANALYSIS; NIDATION; NONHUMAN; SPERMATOGENESIS;

EID: 38949125840     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Plesca-Manea L, Pârvu AE, Pârvu M, Taǎmas M, Buia R. Effects of Melilotus officinalis on acute inflammation. Phytotherapy Res 2002; 16: 316-19.
2. Gebre-Mariam T, Asres K, Getie M, Endale A, Neubert R, Schmidt PC. In vitro availability of kaempferol glycosides from cream formulations of methanolic extract of the leaves of Melilotus. European Journal of pharmaceutics and Biopharmaceutics 2005; 60: 31-38.
3. Asres A, Eder U, Bucar F. Studies on the anti-inflammatory activity of axtracts and compounds from the leaves of Melilotus elegans. Ethiopian Pharmaceutic J 2000; 18: 15-24.
4. Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA. Casual pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999; 22: 157-62.
5. th Camillo Golgi lecture. Diabetologia 2004; 47: 1343-53.
6. OECD Guideline for Testing of Chemicals, Bacterial Reverse Mutation Test 471, OECD Guideline for Testing of Chemicals, In Vitro Mammalian Chromosome Aberration Test 473, OECD Guideline for Testing of Chemicals, Mammalian Erythrocyte Micronucleus Test 474. 1997
7. Maron DM, Ames BN. Revised methods for the Salmonella mutagenicity test. Mutat Res 1983; 113: 173-215.
8. Aeschbacher HU, Finot PA, Wolleb U. Interactions of histidine-containing test substances and extraction methods with the Ames mutagenicity test. Mutat Res 1983; 113: 103-116.
9. Preston RJ, Dean BJ, Galloway S, Holden H, McFee AF, Shelby M. Mammalian In Vivo cytogenetic assays: Analysis of chromosome aberrations in bone marrow cells. Mutat Res 1987; 189: 157-165.
10. Richold M, Chandley A, Ashby J, Gatehouse DG, Bootman J, Henderson L. (1990). In Vivo cytogenetic assays in: DJ Kirkland (Ed) Basic mutagenicity tests, UKEMS recommended procedures. UKEMS subcommittee on guidelines for mutagenicity testing report. Part I revised. Cambridge University Press, Cambridge, New York, Port Chester, Melbourne, Sydney : 115-141.
11. Kumar T, Muralidhara. Male-mediated dominant lethal mutations in mice following prooxidant treatment. Mutation Research/Genetic Toxicity and Environmental Mutagenesis 1999; 444: 145-149.
12. Committee on Mutagenicity of Chemicals in Food, consumer products and the environment (COM) (2000): Guidance on a Strategy for Testing Chemicals for Mutagenicity; 1-36.
13. th collaborative study by CSGMT/JEMS.MMS. Mutat Res 1997; 389: 3- 122.
14. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005; 59(7):365-73.